Investigation préclinique

Membres

Fariba Nemati

Fariba Nemati Equipe LIP Ingénieur de recherche Retour à la liste

Publications clés

Année de publication : 2020

Coussy F, El-Botty R, Château-Joubert S, Dahmani A, Montaudon E, Leboucher S,Morisset L, Painsec P, Sourd L, Huguet L, Nemati F, Servely JL, Larcher T, Vacher S, Briaux A, Reyes C, La Rosa P, Lucotte G, Popova T, Foidart P, Sounni NE, Noel A, Decaudin D, Fuhrmann L, Salomon A, Reyal F, Mueller C, Ter Brugge P, Jonkers J, Poupon MF, Stern MH, Bièche I, Pommier Y, Marangoni E. (2020 Feb 19)

BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers

Science Translational MedicineScience Translational Medicine : DOI : 10.1126/scitranslmed.aax2625
Decaudin Didier, Frisch Dit Leitz Estelle, Nemati Fariba, Tarin Malcy, Naguez Adnan, Zerara Mohamed, Marande Benjamin, Vivet-Noguer Raquel, Halilovic Ensar, Fabre Claire, Jochemsen Aart, Roman-Roman Sergio, Alsafadi Samar. (2020 Jan 9)

Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma.

European Journal of CancerEuropean Journal of Cancer : DOI : 10.1016/j.ejca.2019.12.012